Results 41 to 50 of about 1,197 (161)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System

Frontiers in Immunology, 2018
The induction and modulation of the immune response to vaccination can be rationally designed by combining different vaccine formulations for priming and boosting.
Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, Simone Lucchesi, Gabiria Pastore, Jlenia Brunetti, Francesco Santoro, Peter Andersen, Luisa Bracci, Gianni Pozzi, Donata Medaglini   +10 more
doaj   +1 more source

Computational Analysis of Multiparametric Flow Cytometric Data to Dissect B Cell Subsets in Vaccine Studies

Cytometry Part A, Volume 97, Issue 3, Page 259-267, March 2020., 2020
The generation of the B cell response upon vaccination is characterized by the induction of different functional and phenotypic subpopulations and is strongly dependent on the vaccine formulation, including the adjuvant used. Here, we have profiled the different B cell subsets elicited upon vaccination, using machine learning methods for interpreting ...
Simone Lucchesi, Emanuele Nolfi, Elena Pettini, Gabiria Pastore, Fabio Fiorino, Gianni Pozzi, Donata Medaglini, Annalisa Ciabattini   +7 more
wiley   +1 more source

Differential Immunogenicity and Protective Efficacy Elicited by MTO‐ and DMT‐Adjuvanted CMFO Subunit Vaccines against Mycobacterium tuberculosis Infection

Journal of Immunology Research, Volume 2020, Issue 1, 2020., 2020
Tuberculosis (TB) remains a major and global problem of public health. An effective TB subunit vaccine is urgently needed. Proper selection of the delivery system for the vaccine is crucial for inducing an appropriate immune response tailored to control the target pathogen.
Nadeem Ullah, Ling Hao, Yaqi Wu, Yandi Zhang, Qing Lei, Jo-Lewis Banga Ndzouboukou, Xiaosong Lin, Xionglin Fan, Massimo Ralli   +8 more
wiley   +1 more source

Mycobacterium tuberculosis antigen 85B and ESAT-6 expressed as a recombinant fusion protein in Mycobacterium smegmatis elicits cell-mediated immune response in a murine vaccination model [PDF]

, 2013
This is the post-print version of the final paper published in Molecular Immunology. The published article is available from the link below. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting ...
Aagaard, Agger, Andersen, Andersen, Anthony G. Tsolaki, Bennekov, Blokpoel, Brian D. Robertson, Carroll, Crowe, Curcic, Delogu, Delogu, DeMaio, Dietrich, Dye, Dziadek, Ehrt, Fine, Garbe, Gupta, Hanekom, Ida Rosenkrands, Judit Nagy, Laemmli, Langermans, Maher, Masungi, Menozzi, Menozzi, Okkels, Olsen, O’Donnell, Parish, Pethe, Roche, Russell, Sambrook, Sergio Leiva, Temmerman, Triccas, Triccas, Tsolaki, Uday Kishore, van Dissel, van Dissel, Weinrich Olsen, Wiles, Williams   +48 more
core   +1 more source

Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung [PDF]

Mucosal Immunology, 2017
The capacity of CD4 T cells to protect against Mycobacterium tuberculosis (Mtb) is governed by their ability to localize to the lung site of infection. Subunit vaccine H56/CAF01, a liposome-adjuvanted fusion protein of Mtb antigens Ag85B, ESAT-6, and Rv2660, conferred durable protection and elicited polyfunctional CD4 T cells that preferentially ...
Woodworth, J.S., Cohen, S.B., Moguche, A.O., Plumlee, C.R., Agger, E.M., Urdahl, K.B., Andersen, P.   +6 more
openaire   +2 more sources

Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF®01 or CDA/αGalCerMPEG [PDF]

Vaccines, 2021
This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF®01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF®01 or NG34 + CDA/αGCM.
Sergi López-Serrano, Lorena Cordoba, Mónica Pérez-Maillo, Patricia Pleguezuelos, Edmond J. Remarque, Thomas Ebensen, Carlos A. Guzmán, Dennis Christensen, Joaquim Segalés, Ayub Darji   +9 more
openaire   +7 more sources

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR, Elena Stylianou, Helen McShane, Matthew J. Paul, Rajko Reljic, Resende Co T, Rodriguez A, Uranga S, Wong EA   +8 more
core   +1 more source

Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract [PDF]

Frontiers in Immunology, 2017
The selection of any specific immunization route is critical when defining future vaccine strategies against a genital infection like Chlamydia trachomatis (C.t.). An optimal Chlamydia vaccine needs to elicit mucosal immunity comprising both neutralizing IgA/IgG antibodies and strong Th1/Th17 responses.
Wern, Jeanette Erbo, Sorensen, Maria Rathmann, Olsen, Anja Weinreich, Andersen, Peter, Follmann, Frank   +4 more
openaire   +3 more sources

Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting

Frontiers in Immunology, 2018
Transcriptomic profiling of the immune response induced by vaccine adjuvants is of critical importance for the rational design of vaccination strategies.
Francesco Santoro, Elena Pettini, Dmitri Kazmin, Annalisa Ciabattini, Fabio Fiorino, Gregor D. Gilfillan, Ida M. Evenroed, Peter Andersen, Gianni Pozzi, Donata Medaglini   +9 more
doaj   +1 more source

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [PDF]

, 2014
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of ...
Andersen, Peter, Bang, Peter, Beattie, Trevor, Churchyard, Gavin J., Daubenberger, Claudia, Fielding, Katherine L., Gardiner, Nicolene, Hanekom, Willem A., Hoff, Søren T., Hughes, Elisabeth J., Jeffery, Hannah, Kagina, Benjamin M., Katsoulis, Lynn, Kromann, Ingrid, Landay, Alan, Lenz, Nicole, Mfinanga, Elirehema, Pohl, Christian, Reither, Klaus, Said, Khadija, Scriba, Thomas J.   +20 more
core   +5 more sources